% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{BenKhaled:298980,
      author       = {N. Ben Khaled$^*$ and C. Schulz and M. Alunni-Fabbroni and
                      K. Bronny and L. S. Jochheim and B. Kalali and O. Öcal and
                      M. Seidensticker and I. Piseddu and S. Enssle and M. Karin
                      and J. S. Schneider and T. Strasoldo-Graffemberg and N. Koch
                      and L. Macke and F. P. Reiter and C. M. Lange and Y. Wang
                      and E. N. De Toni$^*$ and M. Gerhard and J. Mayerle and J.
                      Ricke and P. Malfertheiner},
      title        = {{I}mpact of {H}elicobacter pylori on {I}mmune {C}heckpoint
                      {I}nhibition in {H}epatocellular {C}arcinoma: {A}
                      {M}ulticenter {S}tudy.},
      journal      = {Digestion},
      volume       = {106},
      number       = {4},
      issn         = {0012-2823},
      address      = {Basel},
      publisher    = {Karger},
      reportid     = {DKFZ-2025-00400},
      pages        = {303-313},
      year         = {2025},
      note         = {2025;106(4):303-313},
      abstract     = {Immunomodulating effects of Helicobacter pylori (H. pylori)
                      have been shown to inhibit antitumor immunity. Resistance to
                      immune checkpoint inhibitor (ICI)-based therapies is common
                      among patients with hepatocellular carcinoma (HCC). This
                      study aimed to assess the effect of H. pylori on the
                      outcomes of ICI in patients with HCC.We conducted a
                      multicenter study in patients with HCC across a broad range
                      of treatments. Patients received either ICI-based
                      combination regimens or sorafenib-based therapy. H. pylori
                      serostatus and virulence factors were determined and
                      correlated with overall survival (OS), progression-free
                      survival (PFS), and safety across the treatment
                      modalities.180 patients with HCC were included; among these,
                      64 were treated with ICI-based regimen and 116 with
                      sorafenib-based regimen. In patients treated with ICI,
                      median OS was shorter in H. pylori-positive patients (10.9
                      months in H. pylori-positive vs. 18.3 months; p = 0.0384).
                      H. pylori positivity was associated with a shorter PFS in
                      ICI recipients (3.9 months vs. 6.8 months, p = 0.0499). In
                      patients treated with sorafenib, median OS was not shorter
                      among H. pylori-positive patients (13.4 months in H.
                      pylori-positive vs. 10.6 months; p = 0.3353). Immune-related
                      adverse events and rates of gastrointestinal bleeding were
                      comparable between H. pylori-positive and -negative
                      patients.H. pylori seropositivity was linked to poorer
                      outcomes in patients with HCC treated with ICI. This
                      association was not observed among patients receiving
                      sorafenib-based therapies.},
      keywords     = {Helicobacter pylori (Other) / Hepatocellular carcinoma
                      (Other) / Immune checkpoint inhibitor (Other) /
                      Immunotherapy (Other) / Resistance (Other)},
      cin          = {MU01},
      ddc          = {610},
      cid          = {I:(DE-He78)MU01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:39970893},
      doi          = {10.1159/000542847},
      url          = {https://inrepo02.dkfz.de/record/298980},
}